Lexapro is an antidepressant drug owned by Allergan. It contains the active ingredient escitalopram oxalate and was authorized for market use on 14 August, 2002. The therapeutic uses of Lexapro include the treatment of depression and generalized anxiety disorder.
The Lexapro generic will possibly be available after 12 May, 2026. This is due to the expiration of the drug's patent US6916941*PED on 12 February, 2023 and the patent US7420069*PED on the same date. Their expiration dates have been extended due to Pediatric exclusivity which precedes the date of generic availability.
Lexapro is predominantly used for the treatment of major depressive disorder and generalized anxiety disorder. The effectiveness of Lexapro lies in its active ingredient, escitalopram oxalate, which works by helping to restore the balance of certain natural substances in the brain known as neurotransmitters.
Lexapro has a total of 4 patents, all of which have now expired. The last patent, US6916941*PED and US7420069*PED, are due to expire on 12 February, 2023. This is expected to allow for the creation and release of a Lexapro generic. Below are the details of the patent: